The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma
Open accessAbstract
BACKGROUND: The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in more than 90% of patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC in the BCC Outcomes with LDE225 Treatment study. OBJECTIVE: This report provides long-term follow-up data collected up to 12 months after the last patient was randomized. METHODS: In this multicenter, randomized, double-blind phase II study, patients were randomized 1:2 to sonidegib 200 or 800 mg. The primary end point was objective response rate assessed by central review. RESULTS: Objective response rates in the 200- and 800-mg arms were 57.6% and 43.8% in locally advanced BCC and 7.7% and 17.4% in metastatic BCC, respectively. Among the 94 patients with locally advanced BCC who responded, only 18 progressed or died and more than 50% had responses lasting longer than 6 months. In addition, 4 of 5 responders with metastatic BCC maintained an objective response. Grade 3/4 adverse events and those leading to discontinuation were less frequent with sonidegib 200 versus 800 mg (38.0% vs 59.3%; 27.8% vs 37.3%, respectively). LIMITATIONS: No placebo or comparator arms were used because sonidegib demonstrated efficacy in advanced BCC in a phase I study, and the hedgehog pathway inhibitor vismodegib was not yet approved. CONCLUSION: With longer follow-up, sonidegib demonstrated sustained tumor responses in patients with advanced BCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the management of basal cell carcinoma
Telfer, N. R., Colver, G. B., & Morton, C. A. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08666.x · Cited by 960
Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma
Otsuka, A., Dreier, J., Cheng, P. F., Nägeli, M., Lehmann, H., Felderer, L., Frew, I. J., Matsushita, S., Levesque, M. P., & Dummer, R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2110 · Cited by 106
Self-citation
Cited by
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,906
Peris, K., Fargnoli, M. C., Garbe, C., Kaufmann, R., Bastholt, L., Seguin, N. B., Bataille, V., Marmol, V. D., Dummer, R., Harwood, C. A., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.003 · Cited by 599
Self-citationTargeting Cancer Stemness in the Clinic: From Hype to Hope
Saygin, C., Matei, D., Majeti, R., Reizes, O., & Lathia, J. D. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.11.017 · Cited by 517
Lebbe, C., Becker, J. C., Grob, J.-J., Malvehy, J., del Marmol, V., Pehamberger, H., Peris, K., Saiag, P., Middleton, M. R., Bastholt, L., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.06.131 · Cited by 500
Self-citationGuidelines of care for the management of basal cell carcinoma
Bichakjian, C., Armstrong, A., Baum, C., Bordeaux, J. S., Brown, M., Busam, K. J., Eisen, D. B., Iyengar, V., Lober, C., Margolis, D. J., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.10.006 · Cited by 499
Metadata
- Authors
- Dummer, R., Guminski, A., Gutzmer, R., Dirix, L., Lewis, K. D., Combemale, P., Herd, R. M., Kaatz, M., Loquai, C., Stratigos, A. J., Schulze, H.-J., Plummer, R., Gogov, S., Pallaud, C., Yi, T., Mone, M., Chang, A. L. S., Cornélis, F., Kudchadkar, R., Trefzer, U., Lear, J. T., Sellami, D., & Migden, M. R.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 75
- Issue
- 1
- Pages
- 113-125.e5
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W2334577496
- Cited by
- 164
- References
- 2
- FWCI
- 10.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.